IOCN 2025 Conference

The 5th International Online Conference on Nanomaterials

22–24 September 2025 | Online

Nano-Synbiotics: Reprogramming the Gut Microbiome for Personalized Systemic Health

Vasanthi A V*

Department of Pharmacy, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Secunderabad, Telangana, India

INTRODUCTION & AIM

The gut microbiota, a complex ecosystem, regulates immune, metabolic, and neural functions via gut-brain, gut-immune, and gut-metabolic axes. Dysbiosis is linked to chronic conditions like obesity, diabetes, inflammatory bowel disease (IBD), and neurodegeneration. Synbiotics, combining probiotics (e.g., Lactobacillus, Bifidobacterium) and prebiotics (e.g., inulin), aim to restore balance but face challenges like gastric degradation and low bioavailability. Nanotechnology enhances synbiotic delivery, improving precision and efficacy for systemic health. Probiotics in traditional synbiotics suffer up to 90% viability loss in acidic stomach conditions (pH 1.5–3.5).





METHOD

A systematic review of nano-synbiotic technologies reveals a variety of nanocarriers tailored for optimal delivery. Polymeric nanoparticles, such as those made from poly(lactic-co-glycolic acid) (PLGA), offer biodegradability and tunable release profiles, allowing for sustained probiotic delivery over extended periods (Zhang & Li, 2022). Liposomes, lipid-based vesicles, excel in encapsulation efficiency, protecting sensitive microbes while facilitating cellular uptake. Nanogels, composed of cross-linked hydrogels, provide a hydrated environment for probiotic stability and gradual release, ideal for mucoadhesive applications (Kim & Lee, 2022). Solid lipid nanoparticles (SLNs) combine lipid stability with high loading capacity, safeguarding against thermal and chemical stresses during storage and digestion.



Microbiome sequencing (16S rRNA, metagenomics) maps gut profiles, like Firmicutes/Bacteroidetes ratios, linked to metabolic health. AI optimizes personalized synbiotic formulations based on age, diet, and disease (Li & Wang, 2025). Wearable biosensors provide real-time data for dynamic therapy adjustments.

RESULTS & DISCUSSION

Nano-encapsulation boosts probiotic stability, increasing viability in gastric fluids by 50–70% (Gupta & Sharma, 2023). Responsive nanocarriers enhance SCFA production (e.g., butyrate, acetate) by 30–40%, supporting anti-inflammatory and energy-regulating effects (Zhang & Li, 2022). Nano-synbiotics reduce fasting glucose by 15–20% in obesity and type 2 diabetes models, improving insulin sensitivity (Bermudez-Brito & Plaza-Díaz, 2023). In Alzheimer's models, they improve cognitive markers via gut-brain axis modulation, reducing neuroinflammation (Santos & Reis, 2024). In IBD, they lower pro-inflammatory cytokines (TNF-α, IL-6) by 25–35% and strengthen gut barrier integrity (Patel & DuPont, 2021). AI personalization achieves 80% accuracy in tailoring formulations for better outcomes.



Nano-synbiotics achieve 70% probiotic survival, 40% SCFA increase, and 35% inflammation reduction, compared to 30%, 15%, and 10% for conventional synbiotics, demonstrating superior bioavailability and efficacy.

CONCLUSION

Nano-synbiotics revolutionize microbiota modulation with enhanced stability, targeted delivery, and AI-driven personalization, addressing metabolic, neurological, and inflammatory diseases. Future efforts should scale clinical trials, refine AI models, and explore new applications to advance personalized biotherapeutics.

FUTURE WORK / REFERENCES

Rouskas K, Guela M, Pantoura M, Pagkalos I, Hassapidou M, Lalama E, Pfeiffer AFH, Decorte E, Cornelissen V, Wilson-Barnes S, et al. The Influence of an AI-Driven Personalized Nutrition Program on the Human Gut Microbiome and Its Health Implications. Nutrients. 2025; 17(7):1260. https://doi.org/10.3390/nu17071260

Vasanthi, A. V. (2025). Nanotechnology: A Review on Personalized Cancer Therapy and Diagnosis. International Journal of Pharmaceutical and Healthcare Innovation, 2(4), 623-629. https://ijphi.com/index.php/files/issue/view/15